[ad_1]
Another coronavirus vaccine developed in China entered the third phase of clinical trials after animal experiments ended with encouraging results, the manufacturer said Monday.
A vaccine developed by a pharmaceutical company called Walvax Biotechnology in collaboration with researchers at Tsinghua University in Beijing and Tianjin Medical University is based on an adenovirus vector and was prepared with chimpanzee blood. Its mechanism of action is based precisely on the fact that the antibodies capable of neutralizing the adenoviruses carried by chimpanzees are not normally found in the human body. As a result, the vaccine is unlikely to cause an adverse reaction in the human body, but at the same time it provides strong immunity after vaccination, the head of the research group told the Xinhua State News Agency, saying that it was not observed serious side effects in animal experiments.
The third phase of clinical trials of the vaccine will be carried out abroad, in the countries most affected by the epidemic, because there are currently not enough Covid-19 patients in China for this.
Construction of the vaccine production facility began on Sunday in one of Beijing’s southern districts, so that as soon as the results of clinical trials confirm the effectiveness of the vaccine, the facility is ready for mass production. Walwax said the vaccine could receive the necessary permits to enter the market in mid-2021, and the annual production capacity will exceed 200 million doses.
In addition to the Walwax vaccine, five coronavirus vaccines developed in China are currently in the third phase of clinical trials. Among them, the joint vaccine of the Chinese Academy of Military Sciences and Chinese pharmaceutical manufacturer CanSino Biologics is also based on the adenovirus vector.
(MTI)
[ad_2]
